Abstracts tagged "COVID-19"

Abstract Number: 1017 • ACR Convergence 2024
Non-Adherence and Missed Appointments in Rheumatology: Pre and Post COVID-19 Pandemic Impact
Daniela Alejandra Salcedo-Soto¹, Ana Cecilia Bardan-Inchaustegui², Pablo Gamez-Siller³, Deynna Montserrat Lara Mendez⁴, Diana Elsa Flores-Alvarado⁵, Jorge Esquivel-Valerio⁶, Jesus Cardenas-de la Garza² and Dionicio Galarza-Delgado⁷, ¹Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, Mexico, ²Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ³Facultad de Medicina UANL, Monterrey, Nuevo León, Mexico, ⁴Hospital Universitario Dr José Eleuterio González, Monterrey, Nuevo León, Mexico, ⁵Hospital Universitario Jose Eleuterio Gonzalez, Monterrey, Nuevo León, Mexico, ⁶Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, MONTERREY, Mexico, ⁷UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: Rheumatic diseases (RDs) require consistent management with disease-modifying antirheumatic drugs (DMARDs) and regular medical follow-up. However, non-adherence to medication and unattended appointments are common…
Abstract Number: 2025 • ACR Convergence 2024
Autonomic Nervous System Dysfunction Common Among Patients with Long COVID:Diagnosis and Treatment Implications
Norman Gaylis¹, Odence DeLaRosa², Joanne Sagliani¹ and Andrew Holman³, ¹Arthritis & Rheumatic Disease Specialties, Aventura, FL, ²Arthritis & Rheumatic Disease Specialties., Aventura, FL, ³Inmedix, Inc, Seattle, WA
Background/Purpose: Up to 70% of the 236 million people who have been diagnosed with COVID-19 develop some post-COVID symptoms, i.e. post-acute sequalae of SARS-CoV-2 (PASC)…
Abstract Number: 0208 • ACR Convergence 2024
Unlocking COVID-19 Vaccination Choices in Rheumatoid Arthritis: Insights from a Monocentric Study
Hajar Elhani¹, abderrahim majjad², Leila Taoubane³, Najlae Elouardi¹, Hamza Toufik⁴ and AHMED BEZZA⁵, ¹Mohamed V Military Training Hospital, Rheumatology, Rabat, Morocco, Rabat, Morocco, ²military hospital of rabat, rabat, Morocco, ³Mohamed V Military Training Hospital, Rheumatology, Rabat, Morocco, Rabat, ⁴Mohamed V Military Training Hospital, Rheumatology, Rabat, Rabat, Morocco, ⁵Hopital Militaire Med V RABAT, Rabat, Morocco
Background/Purpose: The COVID-19 pandemic has heightened concerns regarding the susceptibility of immunocompromised patients, particularly those with autoimmune diseases like rheumatoid arthritis (RA). Early recommendations from…
Abstract Number: 1104 • ACR Convergence 2024
Long-term Follow-up of Patients with Positive Cryofibrinogen Test During the COVID-19 Era
Carmen Lasa Teja¹, Amparo Sánchez-López², María Enriqueta Peiró³, Mónica Renuncio-García⁴, Adrián Martín-Gutiérrez⁵, Carmen Secada Gómez⁶, Juan Irure-Ventura⁷, Marcos Lopez-Hoyos⁸ and Ricardo Blanco-Alonso⁹, ¹Hospital Universitario Marqués de Valdecilla, Riotuerto, Spain, ²Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ³Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Hospital Universitario Marqués de Valdecilla, Immunology, Santander, Spain, ⁵Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, ⁶Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁷Division of Immunology, Hospital Universitario Marqués de Valdecilla. Immunopathology group, IDIVAL, Santander, Cantabria, Spain, ⁸Division of Immunology, Hospital Universitario Marqués de Valdecilla. Immunopathology group, IDIVAL, Santander, Spain, ⁹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: There have been increasing reports of cutaneous manifestations during COVID‐19 pandemic. An increase in awareness by physicians made them to increase the number of…
Abstract Number: 2044 • ACR Convergence 2024
Clinical Practice Patterns, Rilonacept Appropriate Use for Recurrent Pericarditis
Jessica Farrell¹, Michael Allen², Lee Shapiro³, Victoria Michaels⁴, Arifa Javed⁵, Nabiha Qureshi⁶, Summia Matin Afridi⁷, Shahad Almahmoud⁸, Getzabeth Bosques Gomez⁹ and Khoa Richard Ngo¹⁰, ¹Albany College of Pharmacy & Health Sciences/Albany Medical Center, Delmar, NY, ²Albany Medical Center, Delmar, NY, ³Albany Medical College, Stillwater, NY, ⁴Albany Medical Center, Wynantskill, NY, ⁵Albany Medical Center, Rensselaer, NY, ⁶Albany Medical Center, Menands, NY, ⁷Albany Medical Center, Albany, NY, ⁸Albany College of Pharmacy & Health Sciences/Albany Medical Center, Albany, NY, ⁹Albany College of Pharmacy and Health Sciences/Albany Medical Center, Albany, NY, ¹⁰Albany Medical Center, Voorheesville, NY
Background/Purpose: Pericarditis is inflammation of the pericardial sac which can be of infectious or non-infectious etiology, commonly associated with rheumatic diseases. Pericarditis is defined as…
Abstract Number: 0219 • ACR Convergence 2023
Safety and Efficacy of Pre-Exposure Prophylaxis with Tixagevimab/Cilgavimab (Evusheld) in Patients with Autoimmune Diseases and Renal Involvement Who Received Rituximab
Savino Sciascia¹, MARIA LETIZIA RILAT², ROBERTA FENOGLIO², SILVIA GRAZIETTA FODDAI³, MASSIMO RADIN³, IRENE CECCHI³, giacoma cinnirella², paola crosasso², maria gabriella guidetti², ALICE BARINOTTI³, simone baldovino², ELISA MENEGATTI⁴ and Dario Roccatello⁵, ¹University of Turin, Torino, Italy, ²University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, Turin, Italy, ³University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy, ⁴School of Specialization of Clinical Pathology, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy, ⁵University of Torino, Torino, Italy
Background/Purpose: Patients on B-cell depleting agents may have a suboptimal response to vaccination, placing them at a higher risk of contracting SARS-CoV-2 or suffering from…
Abstract Number: 0810 • ACR Convergence 2023
Telehealth Utilization and Satisfaction Among Patients with Rheumatic Diseases: Trends Since the Onset of the COVID-19 Pandemic
Kristin Wipfler¹ and Kaleb Michaud², ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The COVID-19 pandemic prompted a rapid transition to increased telehealth utilization, with many rheumatology providers replacing in-person clinical visits with telehealth visits or expanding…
Abstract Number: 1629 • ACR Convergence 2023
Persons with Rheumatoid Arthritis and Long COVID Had Worse Pre-COVID RA Symptoms and Worse Non-RA Symptoms, as Well as Higher Rates of Fibromyalgia Compared with COVID Infected Long COVID Negative
Kaleb Michaud¹, Sofia Pedro², Shreena Kamlesh Gandhi³ and Frederick Wolfe², ¹University of Nebraska Medical Center, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³Kansas University School of Medicine, Wichita, KS
Background/Purpose: Long COVID, also known as Post COVID syndrome or postacute sequelae of SARS-CoV-2 infection, refers to the development of persistent or new symptoms lasting…
Abstract Number: 1831 • ACR Convergence 2023
Effect of the COVID-19 Pandemic on Health Status of Fibromyalgia
Tali Sahar¹, Amir Minerbi², maria Verner¹, sabrina Mitrovic³, yoram Shir¹, Gabrielle Page⁴ and mary-ann fitzcharles¹, ¹McGill University, Montreal, QC, Canada, ²Rambam Health Campus, Haifa, Israel, ³McGill University, Montréal-Ouest, QC, Canada, ⁴University of Montreal, Montreal, QC, Canada
Background/Purpose: Fibromyalgia (FM) symptoms fluctuate, with exacerbation commonly associated with stressors. The COVID-19 pandemic was a cause of prolonged stress due to factors such as…
Abstract Number: 2300 • ACR Convergence 2023
Outcomes of COVID-19 Before and During the Omicron Variant Period in Patients with Systemic Lupus Erythematosus: A Global Multicenter Cohort Study Using the TriNetX Network
Wen-Nan Huang¹ and Hsin-Hua Chen², ¹Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Veterans General Hospital, College of Medicine National Chung Hsing University, Department of Business Administration, Ling-Tung University, Taichung, Taiwan; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ²Taichung Veterans General Hospital, Taichung, Taiwan
Background/Purpose: The global dominance of the SARS-CoV-2 Omicron variant ensued shortly after its initial identification in South Africa on November 24, 2021. The outcomes of…
Abstract Number: 0133 • ACR Convergence 2023
COVID-19 Vaccination-related Delayed Adverse Events Among Patients with Systemic Lupus Erythematosus: Results from the COVAD Study
Madiha Fathima¹, Bohdana Doskaliuk², Julius Lindblom¹, Elena Nikiphorou³, Chris Wincup⁴, Sreoshy Saha⁵, Syahrul Sazliyana Shaharir⁶, Wanruchada Katchamart⁷, Phonpen Akarawatcharangura Goo⁸, Lisa Traboco⁹, Yi-Ming Chen¹⁰, Kshitij Jagtap¹¹, James Lilleker¹², Arvind Nune¹³, John Pauling¹⁴, Vishwesh Agarwal¹⁵, Dey Dzifa¹⁶, CARLOS ENRIQUE TORO GUTIERREZ¹⁷, CARLO VINICIO CABALLERO¹⁸, Hector Chinoy¹⁹, Rohit Aggarwal²⁰, Vikas Agarwal²¹, Latika Gupta²² and Ioannis Parodis¹, ¹Karolinska Institutet, Stockholm, Sweden, ²SHEI "Ivano-Frankivsk national medical university", Ivano-Frankivsk, Ukraine, ³King's College London, London, United Kingdom, ⁴King's College Hospital, London, United Kingdom, ⁵Mymensingh Medical College, Faridpur, Bangladesh, ⁶Faculty of Medicine, Universiti Kebangsaan Malaysia, 56000, Cheras, Kuala Lumpur, Malaysia, ⁷Mahidol University, Bangkok, Thailand, ⁸Department of Medicine, Queen Savang Vadhana Memorial Hospital, Chonburi, Thailand, ⁹University of the Philippines - Manila, St Luke's Medical Center - Bonifacio Global City, Paranaque, Manila, Philippines, ¹⁰Taichung Veterans General Hospital, Taichung, Taiwan, ¹¹Seth Gordhandhas Sunderdas Medical College and King Edwards Memorial Hospital, Mumbai, India, ¹²Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK; Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Salford, UK. Orcid ID: 0000-0002-9230-4137., Manchester, United Kingdom, ¹³Southport & Ormskirk NHS Foundation Trust, Liverpool, United Kingdom, ¹⁴North Bristol NHS Trust, Bristol, United Kingdom, ¹⁵Mahatma Gandhi Missions Medical College, Lucknow, India, ¹⁶Department of Medicine and Therapeutics, University of Ghana School of Medicine and Dentistry, College of Health Sciences, Korle-Bu, Accra, Ghana, ¹⁷Centro de Estudios de Reumatología y Dermatología SAS, Cali, Colombia, ¹⁸REUMACARIBE IPS, Barranquilla, Colombia, ¹⁹The University of Manchester, Sale, United Kingdom, ²⁰University of Pittsburgh, Pittsburgh, PA, ²¹Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ²²Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom
Background/Purpose: COVID-19 vaccines have been proven to be safe in healthy populations. However, data on delayed adverse effects (AEs) in people with autoimmune diseases (AIDs),…
Abstract Number: 0220 • ACR Convergence 2023
Paxlovid (Nirmatrelvir Plus Ritonavir) in Patients with Underlying Rheumatological Diseases, in Preventing COVID-19 Related Hospitalization and Death
Faiza Javed, Tony Mangino and Paramarajan Piranavan, University of Kentucky College of Medicine, Lexington, KY
Background/Purpose: The benefits of antiviral therapy in the COVID-19 patients with underlying rheumatic disease with or without immunosuppression are not entirely clear. The goal of…
Abstract Number: 0972 • ACR Convergence 2023
Increased Incidence of Inflammatory Arthritis After COVID-19 in a Colombian Population
Juan Marin¹, Enrique Mazenett¹, Mauricio Sarmiento¹, Rosalbina Perez¹, Claudia Morales¹, Jorge Dominguez¹, Juan Salazar² and Juan-Manuel Anaya³, ¹Coosalud, EPS, Cartagena, Colombia, ²Universidad Nacional, Medellin, Colombia, ³Coosalud, EPS, Bogotá, Colombia
Background/Purpose: An increase in the incidence of autoimmune diseases after COVID-19 has been reported. Since many diseases exhibit population-specific causal effect sizes, we aimed to…
Abstract Number: 1651 • ACR Convergence 2023
Beneficial Effect of Temporary Methotrexate Interruption on B and T Cell Responses upon SARSCoV-2 Vaccination in Patients with Rheumatoid Arthritis or Psoriatic Arthritis
Esther Vicente Rabaneda¹, Pedro Martínez-Fleta², Ana Triguero-Martínez², Emilia Roy³, Miren Uriarte-Ecenarro⁴, Francisco Gutiérrez-Rodríguez⁴, Patricia Quiroga⁴, Ana Romero⁴, Nuria Montes², Laura Esparcia Pinedo², María Aranzazu Alfranca², Rosario Garcia-Vicuna⁵, Francisco Sánchez-Madrid², Isidoro González-Álvaro⁴ and Santos Castañeda⁵, ¹Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ²Division of Immunology, Hospital Universitario de La Princesa, Madrid, Spain, ³Division of Internal Medicine, Hospital Universitario de La Princesa, Madrid, Spain, ⁴Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁵Hospital Universitario de la Princesa, Madrid, Spain
Background/Purpose: Previous published works have raised the concern that methotrexate (MTX) might have a negative effect on immune response upon vaccine administration. At the beginning…
Abstract Number: 1832 • ACR Convergence 2023
Prevalence of Musculoskeletal Manifestations in Post-acute COVID 19 Patients and Their Quality of Life at Kenyatta National Hospital
Miriam Kiyiapi, Omondi Oyoo, Peter Oyiro and Frederick Wangai, University of Nairobi, Nairobi, Kenya
Background/Purpose: Since its discovery in Wuhan, China, severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) has ravaged the globe on an unprecedented scale. While…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.